Low-dose etomidate for the management of severe hypercortisolaemia in different clinical scenarios: a case series and review of the literature

Therapeutic Advances in Endocrinology and Metabolism
Agnieszka Łebek-SzatańskaLucyna Papierska

Abstract

Severe Cushing's syndrome (SCS) is associated with acute cardiovascular, metabolic and infectious complications. It is considered an emergency, requiring an immediate diagnosis, together with a broad spectrum of supportive and hypocortisolaemic treatments. Surgical intervention, aimed at removing the source of cortisol or adrenocorticotropic hormone (ACTH), is the optimal treatment in most cases of Cushing's syndrome. However, in hypercortisolaemic states, surgical intervention has high rates of perioperative mortality and morbidity. Oral adrenal steroidogenesis inhibitors, even if more effective in combination, are not always efficient enough or well tolerated. Despite their common use, a more potent, parental, immediate, and thus life-saving, therapy is necessary. The authors present three different clinical scenarios of etomidate treatment in patients hospitalized in the third reference endocrinological centre in Poland between 2016 and 2017. Patients with Cushing's disease, ectopic Cushing's syndrome and adrenocortical carcinoma presented with severe hypercortisolaemia and exacerbated cortisol-dependent comorbidities. In these three cases, etomidate acted as an accurate, well tolerated and effective cortisol-lowering drug f...Continue Reading

References

Apr 3, 2001·European Journal of Clinical Investigation·M FassnachtB Allolio
Nov 24, 2005·The Journal of Clinical Endocrinology and Metabolism·Andrea M IsidoriG Michael Besser
Mar 31, 2010·Hormone and Metabolic Research = Hormon- Und Stoffwechselforschung = Hormones Et Métabolisme·S HahnerB Allolio
Jul 15, 2011·The Journal of Clinical Endocrinology and Metabolism·Peter KamenickýJacques Young
Sep 16, 2011·The Journal of Clinical Endocrinology and Metabolism·Wiebke ArltPaul M Stewart
Jun 20, 2012·Orphanet Journal of Rare Diseases·Frederic CastinettiThierry Brue
Aug 30, 2012·European Journal of Endocrinology·Lip Min SohWilliam M Drake
Nov 9, 2012·Clinical Endocrinology·R van der PasR A Feelders
Jan 30, 2014·The Journal of Clinical Endocrinology and Metabolism·Frederic CastinettiThierry Brue
Mar 5, 2014·Acta Anaesthesiologica Scandinavica·G ErdoesB Eberle
Jan 28, 2015·European Journal of Endocrinology·Jean-Benoît CorcuffAntoine Tabarin
Jun 13, 2015·Endocrine Reviews·Rosario PivonelloAnnamaria Colao
Jul 30, 2015·The Journal of Clinical Endocrinology and Metabolism·Lynnette K NiemanUNKNOWN Endocrine Society
Jan 8, 2016·Endocrine-related Cancer·Carole GuerinFrederic Castinetti
Feb 3, 2016·Drugs·Krystallenia I Alexandraki, Ashley B Grossman
May 11, 2018·Clinical Case Reports·Alfredo Adolfo Reza-AlbarránLaura Gabriela Gómez Herrera
May 15, 2018·Endocrinology and Metabolism Clinics of North America·Soraya PuglisiMassimo Terzolo
Jun 28, 2018·Endocrinology and Metabolism·Lynnette K Nieman

❮ Previous
Next ❯

Citations

Mar 13, 2021·Best Practice & Research. Clinical Endocrinology & Metabolism·Elena V VarlamovMaria Fleseriu

❮ Previous
Next ❯

Methods Mentioned

BETA
surgical resection
sedation

Related Concepts

Related Feeds

Adrenocortical Carcinoma

Adrenocortical carcinoma (ACC) is a rare malignancy of the adrenal cortex, associated with a generally dismal prognosis owing to its aggressive behavior. Here are the latest discoveries pertaining to this disease.